A phase II investigator-initiated study to evaluate the efficacy and safety of PAI-1 inhibitor TM5614 in patients with SARS-CoV-2 pneumonia
- Funded by Japan Agency for Medical Research and Development (AMED)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Funder
Japan Agency for Medical Research and Development (AMED)Principal Investigator
Professor Hideo HARIGAEResearch Location
JapanLead Research Institution
Graduate School of Medicine, Tohoku UniversiResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Phase 2 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase II
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified